B+
Bull case
25%
Probability
Target price
$1,020.00
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
ARGX
argenx SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The existing VYVGART franchise remains substantial: second-quarter product sales were $1.5 billion, up 60% year over year. Positive ALKIVIA Phase 3 myositis results and FB102 Phase 2 celiac results preserve distinct expansion paths despite UNITY.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
ALKIVIA's dermatomyositis subgroup showed a similar effect magnitude but did not reach statistical significance, creating label-scope uncertainty. [#PR-2026-08-17] Company release
Momentum
31
Value
59
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $840.00 · Bull $1,020.00 · Bear $620.00Analysis 2026-10-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-28 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $1,164.10
Why
Momentum31 · Δ7d -13.1
Value59 · Δ7d -0.2
Sentiment53 · Δ7d -0.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • ALKIVIA's dermatomyositis subgroup showed a similar effect magnitude but did not reach statistical significance, creating label-scope uncertainty. [#PR-2026-08-17] Company release
- • Commercial concentration in VYVGART and rising R&D spending heighten sensitivity to uptake or further trial disappointments. [#PR-2026-07-23] Company results
- • An independent committee recommended stopping Phase 3 UNITY for futility; argenx said the study cannot meet its Sjögren's primary endpoint.
Catalyst clock
2026-10-22
October 22 commercial update tests VYVGART growth
Lead driver: Value · See fundamentals
Momentum
31
8% active weight
Current posture
7d trendImproving
Δ7d
-13.1
Δ21d
-44.9
Value
59
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.5
Sentiment
53
45% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-8.1
Why this grade
Composite grade C. Momentum 31.0 / Value 59.1 / Sentiment 53.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$840.00
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$620.00
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-28
Fundamentals (TTM)
As of 2026-10-28
Market Cap
$55.87B
Beta
0.72
Shares Out
62.89M
P/E (TTM)
34.6
P/S (TTM)
13.68
P/FCF (TTM) · Derived
49.99
Rev YoY
+96.6%
EPS YoY
+272.7%
Gross Margin
+89.5%
Op Margin
+28.8%
Net Debt
-$4.39B
Current Ratio
5.12
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data